.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE56_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE56_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl| name: | InsulinDegludecAndLiraglutide |
| ATC code: | A10AE56 | route: | subcutaneous |
| n-compartments | 2 |
Insulin degludec and liraglutide is a fixed-ratio combination drug used in the treatment of type 2 diabetes mellitus in adults. Insulin degludec is a long-acting basal insulin analog, and liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The combination is approved and used to improve glycemic control in adults with type 2 diabetes inadequately controlled with basal insulin, GLP-1 receptor agonist, or oral antidiabetic drugs.
Estimated pharmacokinetics for adults based on component drugs (insulin degludec and liraglutide), subcutaneous administration, as PK data for the fixed combination are not directly published.